Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 3, 2008, Pages 279-285

  Ota, Satoshi ^a   Wada, Hideo ^a   Abe, Yasunori ^a   Yamada, Eri ^a   Sakaguchi, Akane ^a   Nishioka, Junji ^a   Hatada, Tsuyoshi ^a   Ishikura, Ken ^a   Yamada, Norikazu ^a   Sudo, Akihiro ^a   Uchida, Atsumasa ^a   Nobori, Tsutomu ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

D dimer; F1 + 2; SF; TAT; Thrombosis

Indexed keywords

D DIMER; FIBRIN; PROTHROMBIN; PROTHROMBIN FRAGMENT F1 PLUS F2; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; RISK; THROMBOSIS;

ADULT; AGED; ANTITHROMBIN III; CASE-CONTROL STUDIES; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PROTHROMBIN; RISK FACTORS; SOLUBILITY; THROMBOSIS;

EID: 45749130204     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607309176     Document Type: Article

References (37)

1. Aronson DL, Stevan L., Ball AL, Franza BR Jr, Finlayson JS Generation of the combined prothrombin activation peptide (F1+2) during the clotting of blood and plasma. J Clin Invest. 1977 ; 60: 1410-1418.
2. Pelzer H., Schwarz A., Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost, 1991 ; 65: 153-159
3. Mannucci PM, Bottasso B., Tripodi A., Bonomi AB Prothrombin fragment 1+2 and intensity of treatment with oral anticoagulants. Thromb Haemost. 1991 ; 66: 741.
4. Hafner G., Swars H., Erbel R., et al. Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting. Ann Hematol. 1992 ; 65: 83-87.
5. Takahashi H., Wada K., Niwano H., Shibata A. Comparison of prothrombin fragment 1+2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coag Fibr. 1992 ; 3: 813-818.
6. Asakura H., Shiratori Y., Jokaji H., et al. Changes in plasma levels of prothrombin fragment F1+2 in cases of disseminated intravascular coagulation. Acta Haematol. 1993 ; 89: 22-25.
7. Asakura H., Wada H., Okamoto K., et al. Evaluation of hemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections. Thromb Haemost. 2006 ; 95: 282-287.
8. Levi M., de Jonge E., van der Poll T., Ten Cate H. Disseminated intravascular coagulation. Thromb Haemost. 1999 ; 82: 695-705.
9. Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004 ; 344: 13-21.
10. Okabayashi K., Wada H., Ohta S., Shiku H., Nobori T., Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 2004 ; 76: 225-229.
11. Wada H., Wakita Y., Nakase T., et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost, 1995 ; 74: 848-852.
12. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001 ; 86: 452-463.
13. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000 ; 83: 657-660.
14. Courtney DM, Kline JA Identification of prearrest clinical factors associated with outpatient fatal pulmonary embolism. Acad Emerg Med. 2001 ; 8: 1136-1142.
15. Wells PS, Anderson DR, Rodger M., et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003 ; 349: 1227-1235.
16. Fedullo PF, Tapson VF The evaluation of suspected pulmonary embolism. N Engl J Med. 2003 ; 349: 1247-1255.
17. Linkins LA, Bates SM, Ginsberg JS, Kearon C. Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost. 2004 ; 2: 1256-1260.
18. Le Gal G., Bounameaux H. Diagnosing pulmonary embolism: running after the decreasing prevalence of cases among suspected patients. J Thromb Haemost. 2004 ; 2: 1244-1246.
19. Kline JA, Mitchell AM, Kabrhel C., Richman PB, Courtney DM Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004 ; 2: 1247-1255.
20. Wada H., Sakuragawa N., Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost. 1998 ; 24: 293-297.
21. Lehman CM, Wilson LW, Rodgers GM Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric D-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004 ; 122: 178-184.
22. Wada H., Sase T., Matsumoto T., et al. Increased soluble fibrin in plasma from disseminated intravascular coagulation. Clin Appl Thromb Haemost. 2003 ; 9: 233-240.
23. Tanigawa M., Wada H., Minamikawa K., et al. Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Am J Hematol. 1995 ; 49: 1-5.
24. Saito Y., Wada H., Yamamuro M., et al. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol. 1999 ; 61: 238-242.
25. Wada H., Kaneko T., Ohiwa M., et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993 ; 44: 101-105.
26. Taylor Jr FB, Toh CH, Hoots WK, Wada H., Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86: 1327-1330.
27. Nieuwenhuizen W. A reference material for harmonization of D-dimer assays. Thromb Haemost. 1997 ; 77: 1031-1033.
28. Dempfle CE, Zips S., Ergül H., Heene DL The FACT study group: the fibrin assay comparison trial (FACT), Thromb Haemost. 2001 ; 85: 671-678.
29. Matsuda M., Terukina S., Yamazumi K., Maekawa H., Soe G. A monoclonal antibody that recognizes the NH2-terminal conformation of fragment D. In: Matsuda, Iwanaga, Takada, Henschen A, eds. Fibrinogen 4, Current Basic and Clinical Aspects. Amsterdam: Excerpta Medica; 1990: 43-48.
30. Soe G., Kohno I., Inuzuka K., Itoh Y., Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. Blood. 1996 ; 88: 2109-2117.
31. Goldstein BJ, Mushlin AI Use of a single thyroxine test to evaluate ambulatory medical patients for suspected hypothyroidism. J Gen Intern Med. 1987 ; 2: 20-24.
32. Minamikawa K., Wada H., Wakita Y. et al. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost. 1994 ; 71: 192-194.
33. Yamada N., Wada H., Nakase T., et al. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. Blood Coag Fibr. 1995 ; 6: 627-633.
34. Wada H., Mori Y., Shimura M., Hiyoyama K., et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol. 1998 ; 58: 189-194.
35. Wada H., Mori Y., Kaneko T., et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol. 1993 ; 44: 112-116.
36. Ota S., Wada H., Nobori T., et al. Diagnosis of deep vein thrombosis by plasma-soluble fibrin or D-dimer. Am J Hematol. 2005 ; 79: 274-280.
37. Wada H., Kobayashi T., Abe Y., et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006 ; 6: 1253-1258.